Trial Profile
A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms RAISE
- Sponsors Eli Lilly and Company
- 01 Nov 2019 Results assessing occurance of early adverse events by using data from this study (n= 1057) published in the Targeted Oncology.
- 18 Oct 2018 Results assessing biomarker analysis beyond angiogenesis published in the Annals of Oncology.
- 20 Jan 2018 Results of an analysis assessing patient outcomes by RAS/RAF mutation status, presented at the 2018 Gastrointestinal Cancers Symposium.